Global CDMO Recipharm has signed an MOU, along with His Majesty the King of Morocco, Mohammed VI, the Moroccan Government and a consortium of the country’s leading banks, that will see the company operate a fill finish factory in Morocco.
As part of the agreement, around $500m will be invested by the Moroccan Government and consortium throughout the next five years to establish capacity and capability for the manufacturing of vaccines and biotherapeutics in Morocco.
The investment is aimed to help supply the African continent, enabling it to gain vaccine sovereignty and access to future biotherapeutics.
The factory, which is planned to be operational by 2023, will be run by Recipharm and will mirror the company’s fill finish line at its facility in Monts, France on a larger scale.
Marc Funk, CEO of Recipharm said: “It’s an honour to act as the CDMO of choice on this project. Together with the other parties involved, we will be able to work to offer Africa a concrete opportunity to gradually gain health independence from western countries and ultimately help to ensure it is less vulnerable in times of crisis.
“Our expertise and previous experience of fill finish manufacturing means we’re ideally placed to ensure successful tech transfer and high-quality operations.”
